Evaluation of intravenous voriconazole in patients with compromised renal function - Wikidata - wikimedia - TriplyDB

Evaluation of intravenous voriconazole in patients with compromised renal function

Evaluation of intravenous voriconazole in patients with compromised renal function

http://www.wikidata.org/entity/Q34548752

about

How to manage aspergillosis in non-neutropenic intensive care unit patients Application of caspofungin in China compared with amphotericin B and fluconazole.Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles.Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014.Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment.Role of New Antifungal Agents in the Treatment of Invasive Fungal Infections in Transplant Recipients: Isavuconazole and New Posaconazole Formulations.Voriconazole: Poor Oral Bioavailability and Possible Renal Toxicity in an Infant With Invasive Aspergillosis.

P2860

Q26999448-664AC621-CFFC-4954-BB41-374B7FBDA687 Q34182814-FA97F1D5-1144-4DAC-A229-41B54E1DB7F4 Q35114591-7853D4C0-DB0B-4249-A486-5813093C81B5 Q35617669-57CAB034-10ED-4068-852B-EE76F328A35D Q38284455-457A14AE-74BA-47A6-9D77-12F101A0EC1D Q38644817-B4929902-775B-43C5-8770-B8537E70E7DF Q38939506-468D20AF-DC19-4A50-8F58-72BCB90A0205 Q42101900-719C33E1-658A-4AB2-B57E-3391261A80EE Q47697145-78E9C5A6-4BB5-4E55-8A9C-F10DC56CF75F Q50325686-690A0E5F-FE59-489C-94AF-A037F9ED5DC6

P2860

Evaluation of intravenous voriconazole in patients with compromised renal function

http://www.wikidata.org/entity/Q34548752

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Evaluation of intravenous voriconazole in patients with compromised renal function

@ast

Evaluation of intravenous voriconazole in patients with compromised renal function

@en

Evaluation of intravenous voriconazole in patients with compromised renal function

@nl

type

label

Evaluation of intravenous voriconazole in patients with compromised renal function

@ast

Evaluation of intravenous voriconazole in patients with compromised renal function

@en

Evaluation of intravenous voriconazole in patients with compromised renal function

@nl

prefLabel

Evaluation of intravenous voriconazole in patients with compromised renal function

@ast

Evaluation of intravenous voriconazole in patients with compromised renal function

@en

Evaluation of intravenous voriconazole in patients with compromised renal function

@nl

P1433

Q34548752-5209F363-B70D-45E3-A51D-A1E5DB6E9B50

P1476

Q34548752-9F654590-3C1F-4520-9C76-7FA9FC2E745E

P2093

Q34548752-06862A76-EF88-4407-8E77-D7B39726B73D

Q34548752-088109DA-C4A0-4285-B6BB-57A406AC7053

Q34548752-0A941D80-FD70-417B-96BE-994F35A566CA

Q34548752-4A93053A-6F21-4F92-A1B1-A96AA9C72017

Q34548752-72A1808B-8130-4224-9E07-5889416DA85B

Q34548752-778F12BB-0019-4C42-A814-E43EB646A7B5

P2860

Q34548752-008C936B-1CC0-4840-9441-5BDFC65AC0F1

Q34548752-08C4B135-F39C-456B-A500-9A935258CA0D

Q34548752-16FD53A6-243D-4FD5-9E4D-D70822CC6C21

Q34548752-2004C64A-BF36-462A-88FA-B8BE6F8670F9

Q34548752-266D0008-96FB-4F17-837C-C991E5CCA399

Q34548752-267E0E21-FA25-4036-B10A-CA1080F7F279

Q34548752-3118D61E-A306-4FB4-BF50-09CEEDCBCA9A

Q34548752-33B72373-7F3B-473B-9320-FEFA446644F6

Q34548752-34E627D1-2BCF-4977-BA3F-48EEC9F82810

Q34548752-4744F3FE-EDB0-48AC-87D8-A39BD02DE30B

P2888

Q34548752-89C8E707-5A24-4CA0-BFCB-BA0F22466DAB

P304

Q34548752-83F2AE7B-0CE7-463D-93E9-6E9EA4C93B1C

P31

Q34548752-9FE63B5D-E7FE-4477-B045-64C667BF8A24

P356

Q34548752-0A4E7FEE-EC37-4781-AC7A-2EF7CF674C6E

P478

Q34548752-DA181215-C479-414E-AD41-FC9441F8831B

P577

Q34548752-F0B21783-DC6B-4B18-919B-6DB2CA014E89

P5875

Q34548752-A1F3211B-AD9F-493E-920C-E9B373A96E67

P6179

Q34548752-143794DC-BB21-4BDD-BA74-9907EEA721E6

P698

Q34548752-87677FE5-4A33-4B67-89BE-915419A73CA3

P932

Q34548752-7D3A038A-672A-46F2-B37D-126F0BECA3B6

P356

1471-2334-13-14

P1433

BMC Infectious Diseases

P1476

Evaluation of intravenous voriconazole in patients with compromised renal function

@en

P2093

Craig M Lilly

http://www.w3.org/2001/XMLSchema#string

David R Luke

http://www.w3.org/2001/XMLSchema#string

Joanne Meisner

http://www.w3.org/2001/XMLSchema#string

Paul Ranauro

http://www.w3.org/2001/XMLSchema#string

Thomas Mayer

http://www.w3.org/2001/XMLSchema#string

Verna L Welch

http://www.w3.org/2001/XMLSchema#string

P2860

Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype

A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei

The epidemiology of sepsis in the United States from 1979 through 2000

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Prediction of creatinine clearance from serum creatinine

Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy.

Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.

Acute renal failure associated with Candida albicans infection.

Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration.

Estimating creatinine clearance: a meta-analysis.

P2888

1471-2334-13-14

P304

14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2334-13-14

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234141062

http://www.w3.org/2001/XMLSchema#string

P6179

1044678393

http://www.w3.org/2001/XMLSchema#string

P698

23320795

http://www.w3.org/2001/XMLSchema#string

P932

3584958

http://www.w3.org/2001/XMLSchema#string